BioBrit
11
9M
8
0.92
2
0.27
1
- Areas of investment
Summary
BioBrit appeared to be the Corporate Investor, which was created in 2012.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the BioBrit, startups are often financed by Silicon Valley Bank, Sears Capital Management, Oxford Finance LLC. The meaningful sponsors for the fund in investment in the same round are Sears Capital Management, NEXT Frontier Capital, Mission Bay Capital. In the next rounds fund is usually obtained by Sears Capital Management, NEXT Frontier Capital, Mission Bay Capital.
Among the most popular fund investment industries, there are Therapeutics, Medical. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight SiteOne Therapeutics, Castle Biosciences.
The increased amount of exits for fund were in 2019. The common things for fund are deals in the range of 5 - 10 millions dollars. The fund is constantly included in less than 2 deals per year. The top activity for fund was in 2018. This BioBrit works on 4 percentage points less the average amount of lead investments comparing to the other organizations.
Investments analytics
Analytics
- Total investments
- 11
- Lead investments
- 2
- Exits
- 1
- Rounds per year
- 0.92
- Follow on index
- 0.27
- Investments by industry
- Biotechnology (11)
- Therapeutics (6)
- Health Care (5)
- Health Diagnostics (4)
- Medical (3) Show 3 more
- Investments by region
-
- United States (11)
- Peak activity year
- 2021
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Basilard BioTech | 06 Oct 2021 | Biotechnology, Life Science, Biopharma | Seed | United States, California, California |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.